Pneumonia
is, in fact, the number one killer of young children in many countries.
IN 2008, an estimated 8.8 million children
died before their fifth birthday. One in five of the deaths was due to
pneumonia. Pneumonia kills an estimated 1.4 million children under the age of
five years annually – more than deaths from AIDS, malaria and tuberculosis
combined.
In effect, one child dies from pneumonia every
20 seconds. Most of these pneumonia deaths occur in developing countries.
In Malaysia, the prevalence of pneumonia in
children under five is between 28% and 39%. It is the fifth highest cause of
death in Malaysian children, contributing 4% of deaths under the age of five
years.
This global tragedy becomes even more
depressing if you look at the universal finding that only one in five
caregivers could recognise the danger signs of pneumonia, and only one in five
children with pneumonia actually received lifesaving antibiotics!
Pneumonia often mimics the common cold,
starting with a fever and cough, and parents may not realise that the condition
may be much more serious.
The World Health Organization (WHO) and UNICEF
in their 2008 document outlined the Global Action Plan for Prevention and
Control of Pneumonia (GAPP). In summary, this child survival strategy embraced
the following three key elements:
·Protection by handwashing, exclusive
breastfeeding, improved nutrition, avoidance of indoor pollution (smoking,
stove fires) and reducing risk factors (eg HIV).
·Treatment by improving access to healthcare
and appropriate management at health facilities.
·Prevention of pneumonia by immunising against
germs that are responsible, eg measles, pertussis, Haemophilus influenza B
(Hib) and pneumococcus.
The implementation of the GAPP interventions
to protect (breastfeeding), prevent (vaccinations) and treat (case management)
in the 68 high child mortality countries would potentially avert up to 1.2
million post-neonatal pneumonia deaths annually by 2015.
The prevention strategy with “pneumonia
vaccines” have been shown to substantially reduce pneumonia morbidity and
mortality in children.
Malaysia introduced the pertussis, measles and
Hib vaccines in 1960, 1982 and 2002 respectively. However, the pneumococcal
vaccine is still not in the Health Ministry’s (MOH) National Immunisation
Programme (NIP).
And unfortunately, the pneumococcus is the
number one cause of pneumonia deaths. More than 50% of pneumonia deaths are due
to the pneumococcus.
Apart from pneumonia, the pneumococcus can
cause other serious diseases, namely meningitis (inflammation of the lining of
the spine and brain), bacteraemia (germs in the blood), and other less invasive
but nonetheless very burdensome medical conditions in terms of volume of
morbidity and complications – otitis media (inflammation of the middle ear) and
sinusitis (infection of the sinuses).
For every case of pneumococcal meningitis each
year, there are probably 1,000 cases of pneumococcal otitis media. The two
cases below illustrate the spectrum of diseases caused by the penumococcus.
Case 1: A three-year-old girl presented with a
three week history of coughing and six days of high grade fever. She did not
respond to oral antibiotics and was referred to hospital.
On admission she was febrile, breathing
rapidly and was grunting. Her chest x-ray showed pneumonia of the entire right
lung, with fluid collection. The lung fluid was drained and it grew the
pneumococcus.
She required respiratory support in the
intensive care unit (ICU) for five days, and oxygen support for another five
days. Her repeat chest x-ray showed residual lung damage and she was in
hospital for a total of four weeks.
Case 2: The second case a five-month-old girl
was less fortunate. She had fever 36 hours prior to admission, was feeding
poorly and vomited twice. She was noted to be more sleepy. Both her blood and
cerebrospinal fluid grew pneumococcus.
Despite ventilation in the ICU, intravenous
antibiotics, and close monitoring, she died within 10 hours.
Thus, vaccination against invasive
pneumococcal disease (IPD) is a pivotal life saving strategy and reduces
morbidity because:
·It may prevent children from ever being
infected.
·It reduces the transmission of the bacteria
in the community, thus reducing IPD in other age groups (herd immunity),
·It reduces the need for antibiotics,
resulting in lower rates of resistant bacteria.
The pneumococcal vaccine first introduced in
the US in 2000 has since been shown to be highly efficacious in a wide variety
of populations studied in the US, Gambia and South Africa.
The pneumococcal conjugate vaccine (PCV) is
the first vaccine in 20 years to show a significant reduction in all-cause
child mortality in a major randomised, controlled clinical trial in Gambia,
where seven deaths were prevented for every 1,000 children vaccinated.
The WHO, in a position statement in 2007,
declared: “Recognising the heavy burden of pneumococcal disease in children and
the safety and efficacy of PCV7 in this age group, WHO considers the inclusion
of this vaccine in national immunisation programmes as a priority.”
Looking at the annual world birth cohort in
2008, only 7% have been immunised with the PCV, and most of these were in
developed countries. More than 50 countries have incorporated the PCV in their
NIP. In Asia, only Singapore, Macau and Hong Kong have included PCV in their
NIP.
Since the arrival of the PCV in Malaysia, only
a meagre 10% of our birth cohort have been vaccinated against the pneumococcus,
and virtually all of these were in the private health sector. The vaccine is
not available to the 70-80% of Malaysian children who attend government health
centres for their scheduled immunisations since the PCV is not in the nation’s
NIP.
The Asian Strategic Alliance for Pneumococcal
disease prevention (ASAP) has been at the forefront in the advocacy for the
inclusion of PCV in the NIP of countries in the Asia Pacific. With her
Malaysian partner, the Malaysian Paediatric Association, they were part of the
Global Coalition against Child Pneumonia established in 2009, to advocate for
global action to protect against, effectively treat and help prevent pneumonia.
Datuk Dr MUSA MOHD NORDIN
The Star
Datuk Dr Musa Mohd Nordin is a consultant
paediatrician & neonatologist and is a founding member of the Asian
Strategic Alliance for Pneumococcal disease prevention (ASAP).
Business & Investment Opportunities
YourVietnamExpert is a division of Saigon Business Corporation Pte Ltd, Incorporated in Singapore since 1994. As Your Business Companion, we propose a range of services in Consulting, Investment and Management, focusing three main economic sectors: International PR; Healthcare & Wellness;and Tourism & Hospitality. We also propose Higher Education, as a bridge between educational structures and industries, by supporting international programs. Sign up with twitter to get news updates with @SaigonBusinessC. Thanks.
No comments:
Post a Comment